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Background: Our objective was to conﬁrm the measurement properties of the Treatment Satisfaction Questionnaire with Medication (TQSM) in
patients with cystic ﬁbrosis (CF) receiving inhaled antibiotics.
Methods: The TSQM was included in the EAGER study, a clinical trial comparing a nebulized and a dry powder device for inhaled tobramycin in a
CF population with chronic Pseudomonas aeruginosa (Pa) lung infection, aged 6 years and above (N=553). Reliability and validity of the
questionnaire were investigated using Cronbach's α and multitrait–multimethod approach.
Results: The TSQM demonstrated very good reliability and construct validity: all Cronbach's α were above 0.86 and all items met the convergent
and discriminant validity criteria. In multivariate regressions, higher patient satisfaction and lower perceived impact of side-effects were associated
with better treatment compliance.
Conclusions: The TSQM showed very good measurement properties that strongly support its use to assess satisfaction of patients with CF taking
inhaled antibiotics.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Tobramycin; Patient satisfaction; Patient compliance; Questionnaires1. Introduction
Pseudomonas aeruginosa (Pa) is the most common respira-
tory pathogen found in adult patients with CF and is associated
with deterioration of lung function, frequent hospitalization and
increased risk of mortality [3–5]. Tobramycin inhalation solution
is currently recommended for the management of Pa infection in
CF patients older than 6 years [6,7].
The treatment for CF is complex, burdensome and time-
consuming requiring a range of inhaled and systemic medication,☆ Prior presentations: The data presented in this paper were partially
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Hamburg, Germany) [1,2].
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doi:10.1016/j.jcf.2012.04.007physiotherapy and exercise [8,9]. Treatment of Pa infection with
nebulized antibiotics contributes to this complexity, because of the
length of time involved in set-up, administration, cleaning and
disinfection. This can lead to issues in terms of patient compliance
and persistence. A new drug-device combination, tobramycin
inhalation powder (TIP) hard capsules delivered via the T-326 dry
powder inhaler, was developed to reduce the time needed to
administer the antibiotic and to increase the convenience of the
tobramycin inhalation.
Given its importance in high burden diseases and treatments,
treatment convenience should be evaluated using a scientifically
sound approach and measured with appropriate instruments.
Convenience is frequently considered in the wider framework of
treatment satisfaction: Patient satisfaction theoretical models state
that satisfaction relates to the experience of patients (perceived
efficacy, side-effects, and convenience) [10–12] and therefore
convenience assessment is commonly part of the assessment ofby Elsevier B.V. All rights reserved.
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link patient satisfaction to patient compliance.
Treatment satisfaction has been studied in a number of
different conditions involving various modes of administration
and devices (e.g. eye drops in glaucoma [13] or self-injection in
rheumatoid arthritis [14]). Satisfaction with inhaled therapy has
also been investigated in diseases like asthma [15–18], COPD
[19] and diabetes [20,21]. While the importance of patient-
reported outcomes in CF, in particular health-related quality
of life, has been clearly demonstrated [22], satisfaction with
inhaled therapy has not yet been carefully studied in CF and no
measurement instrument has been investigated in this context.
Our goal was to demonstrate that the Treatment Satisfaction
Questionnaire for Medication (TQSM), a widely used generic
measure of satisfaction with medication, is a valid and reliable
measure of satisfaction in patients with CF and chronic Pa lung
infection treated with inhaled antibiotics. A second objective
was to test in the context of CF the hypotheses about the
relationships between satisfaction, convenience and compliance
derived from patient satisfaction theoretical models, namely:
patient satisfaction is associated to patients' perceived efficacy,
side-effects and convenience; patients who are more satisfied
have better compliance.
2. Materials and methods
2.1. EAGER study design
This article presents post-hoc analyses of data from the
“Establish A new Gold standard Efficacy and safety with
tobramycin in cystic fibRosis” (EAGER) study conducted from
February 2006 to March 2009. The EAGER study was a
randomized, open-label, active-controlled, parallel-arm clinical
trial in subjects with CF aged 6 years or older where the primary
objective was to evaluate the safety of a twice-daily dosing
regimen of TIP delivered by the T-326 Inhaler as compared to
Tobramyin Inhalation Solution (TIS) delivered with the PARI LC
PLUS™ Jet Nebulizer and DeVilbiss PulmoAide™ compressor
or an equivalent alternative. Treatment was administered for
28 days followed by 28 days off therapy (1 cycle) for 3 cycles
over 24 weeks.
In total, 553 CF patients were randomized to TIP or TIS at a
3:2 ratio. To be eligible, patients had to be older than 6 years;
have forced expiratory volume in one second (FEV1) between
25% and 75% predicted based on Knudson equations [23]; and
have sputum or throat cultures positive for Pa within 6 months
of screening.
The study endpoints were safety assessments (including
collection of adverse events and serious adverse events) and
efficacy assessments (such as relative change in FEV1% predicted
from baseline and treatment satisfaction). The key safety and
efficacy results of the EAGER trial have been reported elsewhere
[24].
The EAGER study was approved by an Institutional Review
Board or Independent Ethics Committee for each center and
was conducted in accordance with the Declaration of Helsinki.
Written informed consent was obtained from each patient.2.2. Treatment Satisfaction Questionnaire for Medication (TSQM)
The TSQM version 1 is a 14-item questionnaire designed as
a general measure of treatment satisfaction with medication
[10,25]. Its development involved a literature review about
treatment satisfaction and qualitative research with patients
with chronic illnesses. It was originally validated in a sample of
patients with a variety of chronic conditions (arthritis, asthma,
major depression, type I diabetes, high cholesterol, hyperten-
sion, migraine and psoriasis). The TSQM items are answered
on 5- or 7-point Likert type scale and cover four domains,
corresponding to distinct aspects related to the satisfaction of
patients with their treatment (Effectiveness; Side effects;
Convenience and Global satisfaction). A score can be obtained
for each domain by summing of the corresponding items
transformed on a 0–100 scale; higher values indicate higher
satisfaction, better perceived effectiveness, lower burden
associated to side-effects, better convenience. Of note, patients
who declare experiencing no side-effect automatically have the
highest possible side-effect score (i.e. 100).
A sentence was added to the instructions of the TSQM
included in the EAGER study to specify that the term
“medication”, used throughout the questionnaire, should be
considered as the combination of the medication and the
delivery device. The actual original questions of the TSQM
were not altered.
3. Statistical analyses
All randomized patients who received at least one dose of
study drug and for whom TSQM data were available for at least
one visit were included in analyses, which were performed with
the pooled data from the two treatment arms. All analyses were
performed using SAS software for Windows version 9.2 (SAS
Institute, Cary, NC, USA).
Frequency of missing data and floor and ceiling effects of
TSQM scores (i.e. percentages of patients with respectively the
lowest and highest possible scores) were tabulated.
Construct validity was evaluated using multitrait–multimethod
approach. This approach is based on the correlations between
items and scores [26]. The correlation of an item with its own
domain should be higher than 0.40 (item convergent validity) and
higher than its correlation with all other domains (item
discriminant validity). The correlation coefficients between the
scores were also investigated.
Reliability coefficients were estimated using Cronbach's
coefficient alpha, which assesses internal consistency reliabil-
ity. Reliability coefficients greater than 0.70 were considered
acceptable [27].
Differential item functioning (DIF) between respondents who
were assisted by a relative (patients 12 years of age or less) and
those who responded on their own was also investigated. Patients
who are equally satisfied should give, on average, the same
answer to items assessing satisfaction, regardless of the assistance
given completing the questionnaire. If this is not the case for an
item, then it is said to be functioning differentially [28]. DIF was
sought by using logistic regression, a standard DIF detection
Table 1
Description of study population (N=454).
Analysis sample (N=454)
Age
N 454
Mean (SD) 25.6 (10.8)
Children (b13 years) 42 (9.3%)
Adolescent (13–18 years) 78 (17.2%)
Gender
Male 255 (56.2%)
Race
Asian 4 (0.9%)
Black 4 (0.9%)
Caucasian 409 (90.1%)
Hispanic 34 (7.5%)
Other 3 (0.7%)
Country
United States of America 290 (63.9%)
Canada 4 (0.9%)
Italy 32 (7.1%)
Germany 29 (6.4%)
France 18 (4.0%)
Spain 11 (2.4%)
Netherlands 3 (0.7%)
Greece 2 (0.4%)
Switzerland 1 (0.2%)
United Kingdom 10 (2.2%)
Israel 15 (3.3%)
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considered to characterize DIF, one based on the significance
testing of logistic regression parameters (p-valueb0.01) and the
second based on an estimation of the extent of the difference
between the two groups (effect sizes (ES) should be ≥0.035).
The relative impact of the three TSQM treatment-specific
aspects (Effectiveness, Side effects, and Convenience) on global
satisfaction was investigated by applying structural equation
modeling (SEM) to the TSQM data. SEM is a statistical method
allowing unobserved variables to be studied using the correla-
tions of observed variables [30]. The quality of the hypothesized
models can be evaluated using goodness-of-fit indices, with
associated thresholds for good fit: root mean square error of
approximation (RMSEA) b0.05 (b0.08 for reasonable fit);
normed fit index (NFI)N0.90; root mean residuals (RMR)b
0.05; comparative fit index (CFI)N0.90.
The relationships between TSQM scores and compliance
over cycles 2 and 3 were studied using linear regressions to
explain the percentage of doses taken and logistic regressions to
explain the compliance status (complier: ≥80% doses taken;
non-complier: b80% doses taken), both using the TSQM scores
at the assessment preceding the cycle as explanatory variables.
For both approaches, multivariate models were obtained using
a stepwise selection procedure.Australia 23 (5.1%)
Mexico 8 (1.8%)
Chile 4 (0.9%)
Colombia 4 (0.9%)
FEV1 at baseline (Predicted %)
N 452
Mean (SD) 52.8 (14.5)
Compliance over cycle 1
N 451
Mean percentage of doses taken (SD) 96.5 (10.0)
Compliant patients (≥80% doses taken) 424 (93.4%)
Compliance over cycle 2
N 405
Mean percentage of doses taken (SD) 93.9 (15.0)
Compliant patients (≥80% doses taken) 362 (88.1%)
Compliance over cycle 3
N 379
Mean percentage of doses taken (SD) 93.6 (14.5)
Compliant patients (≥80% doses taken) 331 (86.4%)
SD: Standard deviation; FEV1: Forced expiratory volume in one second.4. Results
4.1. Description of the population
Among the 553 patients randomized in the EAGER trial,
517 received at least one dose of study drug. Of these 517, 460
had available TSQM data for at least one visit; 454 had TSQM
data available at the end of the first treatment cycle (week 5);
411 at the end of the second treatment cycle (week 13) and 383
at the end of the third treatment cycle (week 21).
Mean age of the patients of the analysis population was
25.6 years (Table 1). Most of the patients were male (56.2%)
and Caucasian (90.1%). Patient compliance was very high
(more than 90% of doses were taken over the 3 cycles),
although it decreased slightly over the course of the trial (93.4%
of patients had taken more than 80% of doses over cycle 1 vs.
86.4% over cycle 3).
Among the 517 patients who received at least one dose of
study medication, 217 (42.0%) had a screening FEV1%
predicted between 25% and 50% and 300 (58.0%) between
50% and 75%. Further details on the disease severity of patients
included in the EAGER trial can be found elsewhere [24].4.2. Psychometric properties of the TSQM
4.2.1. Quality of completion and distribution of scores
The psychometric properties of the TSQM were explored
using data from the TSQM assessment at week 5. They were
replicated at week 13 and 21, showing very similar results (data
not shown). At week 5, 95% patients completed all TSQM
items. The item with the most missing data was item 9(“Treatment ease of use”), which was missing for 6 (1.3%)
patients (Table 2).
None of the TSQM scores had a floor effect (Table 3). The
Side effects score showed a strong ceiling effect, with 72% of the
patients having the highest possible score (cases when patients
declare having no side-effects); the Convenience and Global
satisfaction scores had a mild ceiling effect (with 15% and 13%
of patients at the maximum score of 100, respectively).
4.2.2. Construct validity
All items met the item convergent and divergent validity
criteria (Table 3). The pattern of correlations between the
TSQM scores was in line with reasonable assumptions: Global
satisfaction was well correlated with the 3 treatment-specific
Table 2
TSQM items: missing data; differential item functioning (DIF) results (week 5,
N=545).
Items Missing
data a
N (%)
Uniform DIF
p‐
value
ES
Q1. Satisfaction with prevention/treatment 2 (0.4) 0.6141 0.0006
Q2. Satisfaction with symptom relief 2 (0.4) 0.3283 0.0005
Q3. Satisfaction with time to start working 2 (0.4) 0.1752 0.0011
Q4. Side-effect presence 0 (0.0) – –
Q5. Bother from side-effects 0 (0.0) 0.7191 0.0000
Q6. Side-effects interference with physical function 1 (0.7) 0.4215 0.0000
Q7. Side-effects interference with mental function 1 (0.7) 0.9621 0.0073
Q8. Impact of side-effects on satisfaction 1 (0.7) 0.0160 0.0004
Q9. Treatment easy to use 6 (1.3) 0.5533 0.0012
Q10. Easy planning of use 0 (0.0) 0.1433 0.0000
Q11. Intake convenience 0 (0.0) 0.6280 0.0001
Q12. Confidence in benefits 3 (0.7) 0.0107 0.0000
Q13. Balance between good and bad things 2 (0.4) 0.4800 0.0026
Q14. Global satisfaction 0 (0.0) 0.7068 0.0015
ES: Effect Size.
a Q5,Q6,Q7 and Q8 are dependent on Q4 response. Frequencies and percentages
are calculated according to patients who answered Yes at Q4: 138 at week 5, 111 at
week 13 and 92 at week 21.
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with Side-effects); the correlations between these 3 specific
dimensions (which assess fairly independent aspects) were
lower, ranging from 0.20 to 0.43.
4.2.3. Internal consistency
The internal consistency reliability of the TSQM scores was
very good, with Cronbach's alpha ranging from 0.86 for Global
satisfaction to 0.88 for Convenience (Table 3).
4.3. Impact of completion mode
Patients who were assisted when completing the TSQM had
statistically significantly higher Convenience (p=0.016) and
Effectiveness (pb0.001) scores than patients who completed
the questionnaire on their own (Table 3). Global satisfaction
and Side effects scores were also higher for patients who were
assisted when completing the questionnaire than for patients
who answered on their own, but the differences were not
statistically significant.
In the DIF detection phase, neither the mode of completion
nor the interaction between mode of completion and TSQM
score showed a statistically significant effect on any item
responses and all ES were lower than the predefined threshold
of 0.035 (Table 2). Therefore, no item was functioning
differentially between patients who were assisted and those
who were not.
4.4. Exploratory model of treatment satisfaction
A model was prespecified to explore how patient satisfaction
with inhaled antibiotics was formed according to patient
satisfaction theoretical models (Fig. 1): it assumed that the three
treatment-specific TSQM domains (Effectiveness, Convenience;Side effects) affected Global satisfaction. Overall, the fit of this
model to the week 5 data was good, with most of the indices
meeting the predefined criteria (RMSEA=0.09; NFI=0.93;
CFI=0.95; GFI=0.92; AGFI=0.87; standardized RMR=0.06).
Effectiveness showed a strong contribution to Global satisfac-
tion (standardized estimate linking Effectiveness to Global
satisfaction of 0.69). Side effects and Convenience had weaker,
but non-negligible, impacts onGlobal satisfaction (with respective
standardized estimates of 0.17 and 0.21). Similar results were
obtained using TSQM data collected at week 13 and 21 (data not
shown).
4.5. Relationship between TSQM scores and compliance
At week 5, all TSQM scores had a significant relationship
with compliance over the subsequent on-treatment period
(cycle 2=between week 9 and 13) in the univariate linear
regression models (Table 4). Only the Side effects and
Convenience scores were significantly related to compliance
in the multivariate models. These results were very similar for
satisfaction at week 13 and compliance over cycle 3 (between
week 17 and 21).
In the logistic models (when satisfaction was considered
dichotomously, above or below 80% doses taken), compliance
was related to the Side effects and Global satisfaction scores at
week 5 and to Side effects, Effectiveness and Global
satisfaction scores at week 13. In the multivariate models,
Side effects and Global satisfaction (only at week 13) were
significantly associated with compliance status.
5. Discussion
The purpose of this analysis was to investigate satisfaction
with inhaled antibiotics in patients with CF and chronic Pa
infection, with a focus on two main questions: is it appropriate to
use the TSQM to measure satisfaction with inhaled antibiotics in
patients with CF and Pa lung infection; what treatment-related
aspects are key in the formation of patient satisfaction in this
context and to what extent is this satisfaction likely to impact
patient compliance?
The analyses performed on the EAGER study data supported
the good psychometric properties of the TSQM in patients with
CF and chronic Pa infection treated by inhaled tobramycin. The
quality of completion of the fourteen TSQM items was almost
perfect with very few missing answers, the four-domain structure
of the questionnaire was confirmed and the four scores shown to
be reliable. Unfortunately, the extremely small samples from
most of the countries of the study prevented the cross-cultural
validity of the TSQM to be investigated.
Cystic fibrosis commonly affects young patients who may
have difficulties completing on their own a questionnaire about
treatment satisfaction. In the EAGER study, younger patients
were therefore assisted when filling the TSQM and we
investigated whether such assistance impacts the assessment.
A consistent shift in the distribution of all TSQM scores
towards better satisfaction was observed in patients who were
assisted when completing the questionnaire but none of the
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differences in score could not be related to a response bias in
any specific TSQM item. The score differences might be due to
a systematic bias consistently affecting all items, such as social
desirability (the often unconscious desire to give a positive
image to others by giving responses that correspond to socially
admitted opinions [31]). These differences may also be the sign
of a difference in the concepts measured in the context of
different completion mode (it is actually likely that the
satisfaction measured in children is a combination of the parent
and child perspective). Nonetheless, the absence of systematic
difference in TSQM item response, and the small number of
children relative to the total sample clearly support the results
obtained on the overall sample. However, it is critical to note
that our results do not warrant the use of the TSQM to assess
specifically treatment satisfaction in children. The TSQM was
not designed, nor validated in this context of use. Further
research on this topic (both qualitative and quantitative) is
needed to get a better understanding of the question of the
assessment of treatment satisfaction of children with CF and
identify (or develop) an instrument to be used in this purpose.
While the TSQM demonstrated good psychometric proper-
ties in the context of the EAGER study, it would be relevant to
consider assessing satisfaction with inhalers using a measure-
ment instrument specifically designed for this purpose (as has
been done for example in asthma treatment [15]). There may be
specific aspects of CF patients' experience with their inhaled
treatment that are of importance to them but not captured by the
TSQM. Further research on this question is needed to warrant a
proper and comprehensive assessment of satisfaction with the
device in the framework of CF inhaled antibiotic therapy.
Also, the assessment of satisfaction in this study was only in
the context of treatment of Pa infection with inhaled tobramycin.
It could be worthwhile to investigate satisfaction with other
inhaled treatments in CF.While it is likely that these study results
could be directly generalized to other inhaled antibiotics, the
other inhaled therapies (bronchodilators, mucus mobilizers, anti-
inflammatory therapies) have specific features and are used in
different contexts, so they would probably deserve specific
investigations. It might be relevant to scrutinize whether using the
TSQM is appropriate in these various contexts.
Our results showed that the most important driver of
satisfaction with inhaled tobramycin was perceived effective-
ness of the treatment. However, perceived side effects and
convenience appeared to play a non-negligible role in the
formation of satisfaction. This contribution of convenience to
patients' satisfaction confirmed how relevant satisfaction is
when considering delivery devices, for which convenience is a
key feature.
A key reason for studying patient satisfaction is that,
according to theoretical models, satisfaction should affect patient
behavior [10,11,32]. Therefore patient satisfaction with a
treatment is expected to be linked to patient compliance. In our
analyses, a significant association between TSQM scores and
compliance was indeed found, even though the size of the
association was not large. In particular, patients' global
satisfaction was markedly related to compliance. Interestingly,
Fig. 1. Hypothesized TSQM domain measurement models and impact of the three TSQM treatment-specific aspects (Effectiveness, Side effects, and Convenience) on
global satisfaction— results from Structural Equation Modeling (week 5, N=545).This figure summarizes the results of the structural equation model about the link
between treatment satisfaction and patient experience with their treatment (Perceived efficacy, side-effects and convenience). This graphical representation combines
the specification of how each unobserved variable is measured by the items of the questionnaire and the relationships between the unobserved variables. Ovoids
represent unobserved variables; rectangles represent observed variables (items) measuring these unobserved variables; dotted arrows represent the hypothesized links
between the variables; parameters relative to each arrow are standardized parameters (that represent the strength of the association between the linked variables).
499A. Regnault et al. / Journal of Cystic Fibrosis 11 (2012) 494–501the side effect score showed a consistent association with
compliance, independently of global satisfaction. This indicates
the importance of the perceived impact of side effects as a key
driver of patients' behavior regarding their inhaled treatment.
Specifically, among TSQM scores, perceived impact of side
effects was the main factor explaining the fact that some patients
took less than 80% of doses over a cycle. This could indicate that,
even if global satisfaction affects compliance, it is predominantly
the perceived side effects that actually lead to non-compliance.
However, these results should be considered cautiously as they
were obtained from clinical trial data. The clinical trial settingTable 4
Linear and logistic regression results explaining compliance using TSQM scores.
Linear regressi
Univariate
Parameter Estimate p‐
Effect of satisfaction assessed at week 5
on the compliance over cycle 2
Effectiveness 0.09 0.
Side effects 0.18 0.
Convenience 0.07 0.
Global satisfaction 0.14 0.
Effect of satisfaction assessed at week 13
on the compliance over cycle 3
Effectiveness 0.14 0.
Side effects 0.27 b .
Convenience 0.08 0.
Global satisfaction 0.18 b .
In bold, significant estimates at the threshold of 20% for univariate regressions, and
a Linear regression with percentage of doses taken over the cycle as explained va
b Logistic regression with dichotomized compliance (≥80% doses taken vs. b80%imposes conditions that certainly affect compliance. Patients are
selected and aware of being part of a clinical study and rigorous
monitoring is put in place; this naturally translates to very high
levels of compliance (between 93% and 96% of doses were taken,
depending on the cycle considered). Thus, the behaviors observed
in the EAGER trial do not reflect patient behavior in real life. The
limited magnitude of the association between satisfaction and
compliance may be due to this constraining clinical trial context
and global satisfaction may in fact have a greater effect on actual
compliance in real life. However, this possibility can only be
confirmed within an observational real-life study. In addition, theon a Logistic regression b
Multivariate
(after stepwise
selection)
Univariate Multivariate
(after stepwise
selection)
value Estimate p‐value Estimate p‐value Estimate p‐value
0305 – – 0.01 0.3005 – –
0007 0.14 0.0137 0.03 0.0023 0.03 0.0025
0531 – – 0.01 0.0559 – –
0011 0.10 0.0215 0.02 0.0291 – –
0009 – – 0.02 0.0141 – –
0001 0.20 0.0010 0.04 b .0001 0.03 0.0057
0146 – – 0.01 0.0826 – –
0001 0.13 0.0021 0.03 0.0008 0.02 0.0464
at the threshold of 5% for multivariate regressions.
riable.
doses taken) as explained variable.
500 A. Regnault et al. / Journal of Cystic Fibrosis 11 (2012) 494–501analyses of compliance used the threshold of 80% of dose taken to
separate good compliance from poor compliance. While it is a
widely used threshold [33,34], it is not supported by any scientific
rationale in the context of CF and further research about the
definition of good compliance to CF treatment is therefore needed
to support this approach.
In conclusion, the TSQM showed good measurement
properties that strongly support the use of this instrument to
assess patient satisfaction with inhaled CF antibiotic treatments.
In addition, despite the restrictive features related to the clinical
trial setting, an association between patient satisfaction and
compliance was shown: higher patient satisfaction and lower
perceived impact of side effects were found to be associated
with better compliance with CF inhaled treatment.
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